Business Context and Reporting Period
Company: Retractable Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 28, 2021
Reporting Period: Event date July 28, 2021; Contract modification effective immediately.
Key Financial Metrics
This filing reports a specific contract modification rather than periodic financial statements. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics for the period are not provided in this document.
- Contract Modification Value: $50,684,375 (including freight reimbursement).
- Product: VanishPoint low dead space safety syringes.
- Counterparty: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness & Response (DHHS/ASPR).
Material Changes
The Company entered into a modification to a February 2021 contract with DHHS/ASPR. Key changes include:
- Binding Commitment: DHHS/ASPR has committed to exercise options for delivery through December 31, 2021, converting a previously disclosed nonbinding written intent into a binding agreement.
- Revenue Impact: Timing changes and an increase in agreed freight reimbursement result in a slight increase in overall expected revenue under the contract for the exercised option periods.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of a binding commitment for the remainder of 2021 regarding safety syringe deliveries. No forward-looking guidance beyond the contract term or general outlook is provided in this specific report.
Risks and Contingencies: The filing does not disclose new risks or contingencies beyond the standard execution of the government contract modification.
Investor Verification Checklist
- Verify the total value of the contract modification ($50,684,375) and the portion attributable to freight reimbursement versus product sales.
- Confirm the delivery schedule for VanishPoint syringes through December 31, 2021, to assess revenue recognition timing.
- Review prior filings to compare the "nonbinding written intent" previously disclosed against the current binding terms.
- Check subsequent quarterly reports (10-Q) to confirm the actual revenue recognized from this modification.